114 related articles for article (PubMed ID: 15011643)
1. T-1249 development suspended.
Huff B
GMHC Treat Issues; 2003 Dec; 17(12):6. PubMed ID: 15011643
[No Abstract] [Full Text] [Related]
2. The optimal use of enfuvirtide.
Gallant JE
Hopkins HIV Rep; 2003 May; 15(3):1-3. PubMed ID: 12809103
[No Abstract] [Full Text] [Related]
3. Enfuvirtide doubles chances for suppression.
AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
[No Abstract] [Full Text] [Related]
4. Enfuvirtide access, administration, and patient education.
Celano SA
Hopkins HIV Rep; 2003 May; 15(3):1, 12. PubMed ID: 12809102
[No Abstract] [Full Text] [Related]
5. [New drug class blocks virus-cell fusion. HIV not admitted].
MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584215
[No Abstract] [Full Text] [Related]
6. US FDA approves new class of HIV therapeutics.
Robertson D
Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558
[No Abstract] [Full Text] [Related]
7. Fuzeon treatment forum, January 2004.
Burgess GE
Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
[No Abstract] [Full Text] [Related]
8. Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
Edmunds-Ogbuokiri T
HIV Clin; 2007; 19(1):1-3. PubMed ID: 17405221
[No Abstract] [Full Text] [Related]
9. European Commission approves Fuzeon following FDA approval--first HIV-fusion inhibitor in fight against HIV.
Infection; 2003 Aug; 31(4):7-8. PubMed ID: 14562955
[No Abstract] [Full Text] [Related]
10. New partnership calls for clinical testing of two fusion inhibitors.
Slovick J
Posit Living; 1999 Aug; 8(7):15, 62. PubMed ID: 12492078
[No Abstract] [Full Text] [Related]
11. Formal approval for Fuzeon.
AIDS Patient Care STDS; 2004 Dec; 18(12):736. PubMed ID: 15659885
[No Abstract] [Full Text] [Related]
12. The importance of sequencing in treatment options.
Berger DS
Posit Aware; 2001; 12(3):42-3. PubMed ID: 11686121
[No Abstract] [Full Text] [Related]
13. T-20 (Fuzeon) gets priority review.
AIDS Treat News; 2002 Oct; (384):4-5. PubMed ID: 12434762
[No Abstract] [Full Text] [Related]
14. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H
J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697
[No Abstract] [Full Text] [Related]
15. Enfuvirtide approved for defusing HIV.
Burton A
Lancet Infect Dis; 2003 May; 3(5):260. PubMed ID: 12726955
[No Abstract] [Full Text] [Related]
16. Enfuvirtide (Fuzeon).
Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of the clinical development of fusion inhibitor T-1249.
Martin-Carbonero L
AIDS Rev; 2004; 6(1):61. PubMed ID: 15168742
[No Abstract] [Full Text] [Related]
18. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
19. ConFuzeon reigns.
Huff B
GMHC Treat Issues; 2003 Apr; 17(4):10. PubMed ID: 12751446
[No Abstract] [Full Text] [Related]
20. T-20 being called "miraculous".
AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581
[No Abstract] [Full Text] [Related]
[Next] [New Search]
